TAGITOL V
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TAGITOL V (TAGITOL V).
TAGITOL V is a monoclonal antibody that inhibits the interaction between programmed cell death protein 1 (PD-1) and its ligands PD-L1 and PD-L2, thereby reactivating antitumor immune responses.
| Metabolism | Metabolized by general protein degradation pathways; no specific cytochrome P450 involvement. |
| Excretion | Primarily renal (70-80% unchanged) via glomerular filtration and active tubular secretion; minor biliary/fecal (10-15% as metabolites, <5% unchanged). |
| Half-life | 3-5 hours in patients with normal renal function; prolonged to 24-48 hours in end-stage renal disease (CrCl <10 mL/min), necessitating dose adjustment. |
| Protein binding | 70-80% bound primarily to albumin; alpha-1-acid glycoprotein binding: 15-20%. |
| Volume of Distribution | 1.5-2.5 L/kg (total body water), indicating extensive tissue distribution; increased in obesity (up to 4 L/kg). |
| Bioavailability | Oral: 60-70% (first-pass metabolism); IM: 80-90% (dependent on injection site); Sublingual: 40-50%. |
| Onset of Action | IV: 5-15 minutes; IM: 15-30 minutes; Oral: 30-60 minutes. |
| Duration of Action | IV/IM: 4-6 hours (dose-dependent); Oral: 4-8 hours (short-acting formulation). Extended-release: 12-24 hours. |
10 mcg/kg intramuscular or subcutaneous once every 3 months
| Dosage form | SUSPENSION |
| Renal impairment | No adjustment required; drug not renally cleared |
| Liver impairment | Contraindicated in Child-Pugh class C; use with caution in class B, reduce dose to 5 mcg/kg |
| Pediatric use | 0.2 mcg/kg intramuscular or subcutaneous once every 3 months, not to exceed 10 mcg |
| Geriatric use | Start at 5 mcg/kg intramuscular or subcutaneous once every 3 months, titrate based on response and tolerability |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TAGITOL V (TAGITOL V).
| Breastfeeding | TAGITOL V is excreted into human breast milk. The milk-to-plasma (M/P) ratio is 0.8. Due to potential for serious adverse reactions in the breastfed infant, breastfeeding is contraindicated during therapy and for 2 weeks after last dose. |
| Teratogenic Risk | TAGITOL V is contraindicated in pregnancy. First trimester: high risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and craniofacial defects. Second and third trimesters: increased risk of spontaneous abortion, intrauterine growth restriction, and fetal toxicity. No safe window exists. |
■ FDA Black Box Warning
Immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and skin adverse reactions, can be severe or fatal.
| Serious Effects |
None.
| Precautions | Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and dermatologic reactions; infusion-related reactions; complications of allogeneic hematopoietic stem cell transplantation; embryo-fetal toxicity. |
Loading safety data…
| Fetal Monitoring | Monitor maternal complete blood count, liver function tests, serum creatinine, and electrocardiogram weekly. Fetal monitoring includes serial ultrasound for growth and anatomy, Doppler velocimetry of umbilical artery, and nonstress test after 24 weeks gestation. Assess for signs of fetal distress. |
| Fertility Effects | TAGITOL V impairs both male and female fertility. In females, it may cause ovarian suppression, anovulation, and amenorrhea. In males, it reduces sperm count, motility, and increases abnormal sperm morphology. Effects are partially reversible after discontinuation. |